IL36G and neoplasm: Intra-tumoral administration of recombinant IL-36γ (rIL-36γ) in a murine model of an immunologically cold melanoma tumour resulted in increased conventional type 1 and type 2 DCs (cDC1, cDC2), F4/80+ macrophages, Ly6C+ monocytes and neutrophils compared to control B16F10 tumours [74].